


CLAIMS

1. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, aryl, heteroaryl, aryl(C₁-C₆ alkyl), CN, amino, alkylamino, dialkylamino, CF₃, or hydroxyl;

A is selected from the group consisting of a bond, C=O, --SO₂--, --(C=O)NR₀--, and --(CR_aR_b)_q--, where R₀ is H or C₁-C₄ alkyl, and R_a and R_b are independently hydrogen, deuterium, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl, (C₁-C₆ alkyl)heteroaryl, heteroaryl(C₁-C₆ alkyl), and heterocyclic(C₁-C₆ alkyl);

A' is selected from the group consisting of a bond, C=O, --SO₂--, --(C=O)NR₀', --NR₀'(C=O)--, and --(CR_a'R_b')_q--, where R₀' is H or C₁-C₄ alkyl, and R_a' and R_b' are independently hydrogen, deuterium, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl, (C₁-C₆ alkyl)heteroaryl, heteroaryl(C₁-C₆ alkyl), and heterocyclic(C₁-C₆ alkyl);

Z is --(CH₂)_h-- or a bond, where one or more methylene units are optionally substituted by one or more C₁-C₃ alkyl, CN, OH, methoxy, or halo, and where said alkyl may be substituted by one or more fluorine atoms ;

R₁ and R₁' are independently selected from the group consisting of hydrogen, deuterium, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, aryl, heteroaryl, aryl(C₁-C₆ alkyl), CN, amino, alkylamino, dialkylamino, alkoxy, heteroaryl(C₁-C₆ alkyl), and heterocyclic(C₁-C₆ alkyl), wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C₁-C₆ alkyl, halo, CN, hydroxy, methoxy, amino, C₁-C₄ alkyl amino, di(C₁-C₄ alkyl)amino, CF₃, --SO₂-(C₁-C₆ alkyl), and C₃-C₆ cycloalkyl;

R₂ is selected from the group consisting of hydrogen, deuterium, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms;


R₃ is selected from the group consisting of hydrogen, deuterium, and amino;

R₄ is monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C₁-C₆ alkyl, heterocycloalkyl, halo, CN, hydroxy, --CO₂H, C₁-C₆ alkoxy, amino, --N(C₁-C₆ alkyl)(CO)(C₁-C₆ alkyl), --NH(CO)(C₁-C₆ alkyl), --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), --(CO)N(C₁-C₆ alkyl)₂, --(C₁-C₆ alkyl)amino, --N(C₁-C₆ alkyl)₂, --SO₂-(C₁-C₆ alkyl), --(SO)NH₂, and C₃-C₆ cycloalkyl, where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C₁-C₆ alkyl, halo, CN, OH, alkoxy, amino, --CO₂H, --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), or --(CO)N(C₁-C₆ alkyl)₂, and where said alkyl may be further substituted by one or more fluorine atoms;

R₅ is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, and hydroxyl;

h is 1, 2 or 3; j and k are independently 0, 1, 2, or 3; m and n are independently 0, 1 or 2; and, q is 0, 1 or 2.

2. The compound of claim 1 having the structure:



or a pharmaceutically acceptable salt thereof, wherein

A' is a bond and R_1' is H,

X is N;

A is selected from the group consisting of a bond, $C=O$, $-SO_2-$, $-(C=O)NR_0-$, and $-(CR_aR_b)_q-$, where R_0 is H or C_1-C_4 alkyl, and R_a and R_b are independently hydrogen, deuterium, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, aryl, aryl(C_1-C_6 alkyl), heteroaryl, (C_1-C_6 alkyl)heteroaryl, heteroaryl(C_1-C_6 alkyl), and heterocyclic(C_1-C_6 alkyl);

R_1 is selected from the group consisting of hydrogen, deuterium, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, aryl, heteroaryl, aryl(C_1-C_6 alkyl), CN, amino, alkylamino, dialkylamino, fluoroalkyl, alkoxy, heteroaryl(C_1-C_6 alkyl), heterocyclic and heterocyclic(C_1-C_6 alkyl), wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C_1-C_6 alkyl, halo, CN, hydroxy, methoxy, amino, C_1-C_4 alkyl amino, di(C_1-C_4 alkyl)amino, CF_3 , $-SO_2-(C_1-C_6$ alkyl), and C_3-C_6 cycloalkyl;

R_2 is selected from the group consisting of hydrogen, deuterium, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms;


R₃ is selected from the group consisting of hydrogen and deuterium;

R₄ is monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C₁-C₆ alkyl, heterocycloalkyl, halo, CN, hydroxy, --CO₂H, C₁-C₆ alkoxy, amino, --N(C₁-C₆ alkyl)(CO)(C₁-C₆ alkyl), --NH(CO)(C₁-C₆ alkyl), --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), --(CO)N(C₁-C₆ alkyl)₂, --(C₁-C₆ alkyl)amino, --N(C₁-C₆ alkyl)₂, --SO₂-(C₁-C₆ alkyl), --(SO)NH₂, and C₃-C₆ cycloalkyl, where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C₁-C₆ alkyl, halo, CN, OH, alkoxy, amino, --CO₂H, --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), or --(CO)N(C₁-C₆ alkyl)₂, and where said alkyl may be further substituted by one or more fluorine atoms;

h is 1, 2 or 3; *j* is 0, 1, 2, or 3; and, *q* is 0, 1 or 2.

R₅ is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, and hydroxyl;

3. The compound of claim 1 having the structure:



or a pharmaceutically acceptable salt thereof, wherein

A' is a bond and R₁' is H,

X is N;

A is selected from the group consisting of a bond, C=O, --SO₂--, --(C=O)NR₀--, and --(CR_aR_b)_q--, where R₀ is H or C₁-C₄ alkyl, and R_a and R_b are independently

hydrogen, deuterium, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl, (C₁-C₆ alkyl)heteroaryl, heteroaryl(C₁-C₆ alkyl), and heterocyclic(C₁-C₆ alkyl);


R₁ is selected from the group consisting of hydrogen, deuterium, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, aryl, heteroaryl, aryl(C₁-C₆ alkyl), --CN, amino, alkylamino, dialkylamino, fluoroalkyl, alkoxy, heteroaryl(C₁-C₆ alkyl), heterocyclic and heterocyclic(C₁-C₆ alkyl), wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C₁ - C₆ alkyl, halo, CN, hydroxy, methoxy, amino, C₁-C₄ alkyl amino, di(C₁-C₄ alkyl)amino, CF₃, --SO₂-(C₁-C₆ alkyl), and C₃-C₆ cycloalkyl;

R₂ is selected from the group consisting of hydrogen, deuterium, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms;

R₃ is selected from the group consisting of hydrogen and deuterium;

R₄ is monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C₁-C₆ alkyl, heterocycloalkyl, halo, CN, hydroxy, --CO₂H, C₁-C₆ alkoxy, amino, --N(C₁-C₆ alkyl)(CO)(C₁-C₆ alkyl), --NH(CO)(C₁-C₆ alkyl), --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), --(CO)N(C₁-C₆ alkyl)₂, --(C₁-C₆ alkyl)amino, --N(C₁-C₆ alkyl)₂, --SO₂-(C₁-C₆ alkyl), --(SO)NH₂, and C₃-C₆ cycloalkyl, where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C₁-C₆ alkyl, halo, CN, OH, alkoxy, amino, --CO₂H, --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), or --(CO)N(C₁-C₆ alkyl)₂, and where said alkyl may be further substituted by one or more fluorine atoms; R₅ is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, and hydroxyl; *j* is 0, 1, 2, or 3; and, *q* is 0, 1 or 2.

4. The compound of claim 1 having the structure:



or a pharmaceutically acceptable salt thereof, wherein

A' is selected from the group consisting of a bond, C=O, --SO₂--, --(C=O)NR₀', --NR₀'(C=O)--, and --(CR_a'R_b')_q--, where R₀' is H or C₁-C₄ alkyl, and R_a' and R_b' are independently hydrogen, deuterium, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl, (C₁-C₆ alkyl)heteroaryl, heteroaryl(C₁-C₆ alkyl), and heterocyclic(C₁-C₆ alkyl);

R₁' is selected from the group consisting of hydrogen, deuterium, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, aryl, heteroaryl, aryl(C₁-C₆ alkyl), CN, amino, alkylamino, dialkylamino, fluoroalkyl, alkoxy, heteroaryl(C₁-C₆ alkyl), heterocyclic and heterocyclic(C₁-C₆ alkyl), wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C₁-C₆ alkyl, halo, CN, hydroxy, methoxy, amino, C₁-C₄ alkyl amino, di(C₁-C₄ alkyl)amino, CF₃, --SO₂-(C₁-C₆ alkyl), and C₃-C₆ cycloalkyl;

R₂ is selected from the group consisting of hydrogen, deuterium, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms;

R₃ is selected from the group consisting of hydrogen and deuterium;

R₄ is monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C₁-C₆ alkyl, heterocycloalkyl, halo, CN, hydroxy, --CO₂H, C₁-C₆ alkoxy, amino, --N(C₁-C₆ alkyl)(CO)(C₁-C₆ alkyl), --NH(CO)(C₁-C₆ alkyl), --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), --(CO)N(C₁-C₆ alkyl)₂, --(C₁-C₆ alkyl)amino, --N(C₁-C₆ alkyl)₂, --SO₂-(C₁-C₆ alkyl), --(SO)NH₂, and C₃-C₆

cycloalkyl, where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C₁-C₆ alkyl, halo, CN, OH, alkoxy, amino, --CO₂H, --(CO)NH₂, --(CO)NH(C₁-C₆ alkyl), or --(CO)N(C₁-C₆ alkyl)₂, and where said alkyl may be further substituted by one or more fluorine atoms;

R₅ is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, and hydroxyl;

R₇ and R₈ are independently hydrogen, C₁-C₄ alkyl, aryl, heteroaryl, (aryl)C₁-C₆ alkyl, (heteroaryl)C₁-C₆ alkyl, (heterocyclic)C₁-C₆ alkyl, (C₁-C₆ alkyl)aryl, (C₁-C₆ alkyl)heteroaryl, or (C₁-C₆ alkyl)heterocyclic, wherein said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, CF₃, and C₃-C₆ cycloalkyl;

k is 0, 1, 2, or 3; *m* and *n* are both 1; and, *q* is 0, 1 or 2.

5. A compound of claim 1 selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl]{[(1R,5S)-3-[2-({5-fluoro-6-[(3S)-3-hydroxypyrrolidin-1-yl]pyridin-3-yl}amino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

(1R,5S)-N-ethyl-3-[2-(1,2-thiazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

(1R,5S)-3-(2-[[5-chloro-6-(methylcarbamoyl)pyridin-3-yl]amino]pyrimidin-4-yl)-N-ethyl-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

cyclopropyl[(1R,5S)-3-(2-[[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]amino]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-[1-(methylsulfonyl)azetidin-3-yl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

4-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,6-dimethylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-[(1R,2S)-2-fluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-N,3-dimethylpyridine-2-carboxamide;

cyclopropyl[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

3-[(1R,5S)-3-{2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]butanenitrile;

5-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-N-ethyl-3-methylpyridine-2-carboxamide;

3-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]butanenitrile;

5-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-3-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[[5-fluoro-6-(methylcarbamoyl)pyridin-3-yl]amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

3-chloro-5-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-N-methylpyridine-2-carboxamide;

(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-N-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

(3,3-difluorocyclobutyl)[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

1-({[(1R,5S)-3-{2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl}methyl)cyclopropanecarbonitrile;

3-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]butanenitrile;

(1S,2R)-2-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl)cyclopropanecarbonitrile;

(1R,2S)-2-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl)cyclopropanecarbonitrile;

[(1R,2R)-2-fluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1R,2R)-2-fluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;
 (1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;
 (1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-N-[5-(trifluoromethyl)pyridin-2-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;
 N,3-dimethyl-5-[(4-{(1R,5S)-8-[(3-methyloxetan-3-yl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino]pyridine-2-carboxamide;
 {3-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]-1-(methylsulfonyl)azetidin-3-yl}acetonitrile;
 4-({4-[8-(cyanoacetyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N-ethylbenzamide;
 (1R,5S)-N-(cyanomethyl)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;
 5-({4-[(1R,5S)-8-[(1S,2R)-2-fluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-N,3-dimethylpyridine-2-carboxamide;
 5-({4-[(1R,5S)-8-(cis-3-cyanocyclobutyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;
 5-({4-[(1R,5S)-8-[(1R)-2,2-difluorocyclopropyl]methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-N,3-dimethylpyridine-2-carboxamide;
 N,3-dimethyl-5-({4-[(1R,5S)-8-(1,2-oxazol-5-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)pyridine-2-carboxamide;
 2-[5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)pyridin-2-yl]-2-methylpropanenitrile;
 3-[(1R,5S)-3-{2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]propanenitrile;
 (1R,5S)-N-ethyl-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-(2-{[5-fluoro-6-(2-hydroxyethyl)pyridin-3-yl]amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-(2-{[5-fluoro-6-(3-hydroxyazetidin-1-yl)pyridin-3-yl]amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1R,5S)-3-(2-{[5-chloro-6-(2-hydroxyethoxy)pyridin-3-yl]amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-8-yl][(1S)-2,2-difluorocyclopropyl]methanone;

{3-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]oxetan-3-yl}acetonitrile;

[(1R,5S)-3-(2-{[5-chloro-6-(2-hydroxyethyl)pyridin-3-yl]amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-8-yl][(1S)-2,2-difluorocyclopropyl]methanone;

2-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]pyridine-4-carbonitrile;

3-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]cyclobutanecarbonitrile;

2-[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]-1,3-oxazole-5-carbonitrile;

(1R,5S)-N-(2-cyanoethyl)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-(1,2-oxazol-4-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

4-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-6-(hydroxymethyl)-N-methylpyridine-2-carboxamide;

(1-fluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-(1,3-thiazol-2-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

cyclopropyl{(1R,5S)-3-[2-(1,2-thiazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-[2-(5-fluoro-6-[(3R)-3-hydroxypyrrolidin-1-yl]pyridin-3-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-N,3-dimethylpyridine-2-carboxamide;

4-[(1R,5S)-8-[(1R)-2,2-difluorocyclopropyl]methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine;

6-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-5-fluoropyrimidin-2-yl}amino)imidazo[1,2-a]pyridine-2-carboxamide;

5-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-5-fluoropyrimidin-2-yl}amino)pyridine-2-sulfonamide;

5-({4-[(1R,5S)-8-(trans-3-cyanocyclobutyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;

1,2-oxazol-5-yl{(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-(methylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

(1S,2S)-2-([(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl)methyl]cyclopropanecarbonitrile;

3-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-5-fluoropyrimidin-2-yl}amino)-N-propyl-1H-pyrazole-5-carboxamide;

(1S,2S)-2-([(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl)methyl]cyclopropanecarbonitrile;

cyclopropyl{(1R,5S)-3-[5-fluoro-2-(pyridazin-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

4-({4-[6-(2,2-difluoropropanoyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]-5-fluoropyrimidin-2-yl}amino)-N-ethyl-2-methylbenzamide;

(1S,2S)-2-cyano-N-[(1S,5R,6R)-3-(2-[[6-(2-hydroxyethoxy)pyridin-3-yl]amino]-5-methylpyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

N-[(1S,5R)-3-(5-chloro-2-[[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]amino]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-(5-fluoro-2-[[1-(oxetan-3-yl)-1H-pyrazol-4-yl]amino]pyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1S)-2,2-difluoro-N-[(1S,5S)-3-(5-fluoro-2-[[1-methyl-1H-pyrazol-4-yl]amino]pyrimidin-4-yl)-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

N-[(1S,5R,6R)-3-(5-fluoro-2-({6-[(2S)-1-hydroxypropan-2-yl]pyridin-3-yl}amino)pyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

5-[(4-[(1S,5R,6R)-1-[(cyclopropylcarbonyl)amino]-6-methyl-3-azabicyclo[3.1.0]hex-3-yl]-5-fluoropyrimidin-2-yl)amino]-N,3-dimethylpyridine-2-carboxamide;

N-[(1S,5R,6R)-3-[2-({5-chloro-6-[(1R)-1-hydroxyethyl]pyridin-3-yl}amino)-5-fluoropyrimidin-4-yl]-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R)-2,2-difluoro-N-[(1R,5S,6S)-3-(5-fluoro-2-[[1-methyl-1H-pyrazol-4-yl]amino]pyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

5-[(4-[(1R,5S,6S)-1-[(cyclopropylcarbonyl)amino]-6-methyl-3-azabicyclo[3.1.0]hex-3-yl]-5-fluoropyrimidin-2-yl)amino]-N,3-dimethylpyridine-2-carboxamide;

N-[(1R,5S)-3-(5-chloro-2-[[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]amino]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide; N-[(1S,5R,6R)-3-(5-fluoro-2-({6-[(2R)-1-hydroxypropan-2-yl]pyridin-3-yl}amino)pyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide; and, (1S)-2,2-difluoro-N-[(1R,5S,6S)-3-(5-fluoro-2-[(1-

methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

or, a pharmaceutically acceptable salt thereof.

6. A compound of claim 2, selected from the group consisting of:

N-ethyl-4-({5-fluoro-4-[6-(2-fluoro-2-methylpropanoyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)-2-methylbenzamide; N-ethyl-4-({5-fluoro-4-[6-(trifluoroacetyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)-2-methylbenzamide; N-ethyl-2-methyl-4-({4-[6-(trifluoroacetyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)benzamide; 4-({4-[6-(cyclopropylcarbonyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)-N-ethyl-2-methylbenzamide; and, 4-({4-[6-(2,2-difluoropropanoyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]pyrimidin-2-yl}amino)-N-ethylbenzamide;

or, a pharmaceutically acceptable salt thereof.

7. A compound of claim 3, selected from the group consisting of:

4-({4-[8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-5-fluoropyrimidin-2-yl}amino)-N-ethylbenzamide;

N-ethyl-4-({5-fluoro-4-[8-(trifluoroacetyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-2-methylbenzamide;

(1R,5S)-3-(2-{{5-methyl-6-(methylcarbamoyl)pyridin-3-yl}amino}pyrimidin-4-yl)-N-(2,2,2-trifluoroethyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

(1R,5S)-N-(cyanomethyl)-3-(2-{{5-methyl-6-(methylcarbamoyl)pyridin-3-yl}amino}pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

5-({4-[(1R,5S)-8-{{(1S)-2,2-difluorocyclopropyl}carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;

tert-butyl 3-(2-{{4-(ethylcarbamoyl)-3-methylphenyl}amino}-5-fluoropyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate;

5-({4-[(1R,5S)-8-([(1R,2R)-2-cyanocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;

3-chloro-5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N-methylpyridine-2-carboxamide; N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-(1,2-thiazol-5-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

[(1S)-2,2-difluorocyclopropyl]({(1R,5S)-3-[2-({6-[(2S)-1-hydroxypropan-2-yl]pyridin-3-yl}amino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

3-chloro-5-({4-[(1R,5S)-8-([(1R,2R)-2-cyanocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N-methylpyridine-2-carboxamide;

[(1S)-2,2-difluorocyclopropyl]({(1R,5S)-3-[2-({5-fluoro-6-(hydroxymethyl)pyridin-3-yl}amino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

5-([4-({(1R,5S)-8-[(2,2-difluorocyclopropyl)carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-(cyclopropylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-N,3-dimethylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-[2-({5-methyl-6-(methylcarbamoyl)pyridin-3-yl}amino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1S)-2,2-difluorocyclopropyl]({(1R,5S)-3-[2-({6-[(2R)-1-hydroxypropan-2-yl]pyridin-3-yl}amino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

N-(1-methyl-1H-pyrazol-4-yl)-4-[(1R,5S)-8-(1,2-oxazol-5-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-amine;

cyclopropyl({(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;

5-({4-[(1R,5S)-8-([(1R,2R)-2-cyanocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

[(1R)-2,2-difluorocyclopropyl]({(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone; and,

5-({4-[(1R,5S)-8-([(1R)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

or, a pharmaceutically acceptable salt thereof.

8. A compound of claim 4, selected from the group consisting of:

(1R)-2,2-difluoro-N-[(1S,5R,6R)-3-(5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

N-[(1S,5R,6R)-3-(2-{[5-chloro-6-(hydroxymethyl)pyridin-3-yl]amino}-5-fluoropyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide; and,

N-[(1S,5R,6R)-3-(5-fluoro-2-[[6-(2-hydroxyethyl)pyridin-3-yl]amino]pyrimidin-4-yl)-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

or, a pharmaceutically acceptable salt thereof.

9. A compound of claim 1, where the compound is [(1S)-2,2-difluorocyclopropyl]({(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone; or, a pharmaceutically acceptable salt thereof.

10. A compound of claim 1, where the compound is [(1S)-2,2-difluorocyclopropyl]({(1R,5S)-3-[2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone; or, a pharmaceutically acceptable salt thereof.

11. A compound of claim 1, wherein the compound is 5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide; or, a pharmaceutically acceptable salt thereof.

12. A compound of claim 1, wherein the compound is (1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide; or, a pharmaceutically acceptable salt thereof.

13. A compound of claim 1, wherein the compound is [(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone; or, a pharmaceutically acceptable salt thereof.

14. A compound of claim 1, wherein the compound is (1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide, or, a pharmaceutically acceptable salt thereof.

15. A compound of claim 1, wherein the compound is (1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide or, a pharmaceutically acceptable salt thereof.

16. The compound which is (1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide; or, a pharmaceutically acceptable salt thereof.

17. A compound of claim 1, wherein the compound is (1R,2R)-2-[[[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl]cyclopropanecarbonitrile; or, a pharmaceutically acceptable salt thereof.

18. A compound of claim 1, wherein the compound is 4-((1R,5S)-8-((2,2-difluorocyclopropyl)methyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-N-(1H-pyrazol-4-yl)pyrimidin-2-amine; or, a pharmaceutically acceptable salt thereof.

19. A compound of claim 1, wherein the compound is 5-((4-((1R,5S)-8-(((1S)-2,2-difluorocyclopropyl)carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)pyrimidin-2-yl)amino)-3-methylpyridine-2-carboxamide; or, a pharmaceutically acceptable salt thereof.

20. A compound of claim 1, wherein the compound is 5-((4-((1R,5S)-8-(((1S)-2,2-difluorocyclopropyl)carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)pyrimidin-2-yl)amino)-3-fluoropyridine-2-carboxamide; or, a pharmaceutically acceptable salt thereof.

21. A pharmaceutical or a veterinary composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. A compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-((4-((1R,5S)-8-(((1S)-2,2-difluorocyclopropyl)carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)pyrimidin-2-yl)amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl]cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-3-methylpyridine-2-carboxamide; 5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-3-fluoropyridine-2-carboxamide; and, 4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, for use in the treatment of psoriasis, vitiligo, alopecia, or atopic dermatitis.

23. Use of a compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl]cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-methylpyridine-2-carboxamide; 5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-fluoropyridine-2-carboxamide; and, 4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of psoriasis, vitiligo, alopecia, or atopic dermatitis.

24. A compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl]cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl)amino)-3-fluoropyridine-2-carboxamide
and,

4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, for use in the treatment of systemic lupus erythematosus or lupus nephritis.

25. Use of a compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-(1H-pyrazol-4-yl)amino}pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-([(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl)cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoropyridine-2-carboxamide and,

4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of systemic lupus erythematosus or lupus nephritis.

26. A compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-([(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl)cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-fluoropyridine-2-carboxamide

and,

4-((1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl)-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, for use in the treatment of primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis.

27. Use of a compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl]cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl)amino)-3-fluoropyridine-2-carboxamide

and,

4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis.

28. A compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl]cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoropyridine-2-carboxamide
and,

4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, for use in the treatment of inflammatory bowel disease, Crohn's disease, or ulcerative colitis.

29. Use of a compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-([(1S)-2,2-difluorocyclopropyl]carbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-([(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl)cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-{[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl}amino)-3-methylpyridine-2-carboxamide;
 5-({4-[(1R,5S)-8-{[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl}amino)-3-fluoropyridine-2-carboxamide
 and,
 4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;
 or, a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of inflammatory bowel disease, Crohn's disease, or ulcerative colitis.

30. A compound selected from the group consisting of:
 [(1S)-2,2-difluorocyclopropyl]{(1R,5S)-3-[2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;
 [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;
 5-({4-[(1R,5S)-8-{[(1S)-2,2-difluorocyclopropyl]carbonyl}-3,8-diazabicyclo[3.2.1]oct-3-yl}pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;
 (1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;
 [(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl}methanone;
 (1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;
 (1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-[[[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl}cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoropyridine-2-carboxamide
and,

4-[(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, for use in the treatment of multiple sclerosis.

31. Use of a compound selected from the group consisting of:

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-(1H-pyrazol-4-ylamino)pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

5-({4-[(1R,5S)-8-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoro-N-methylpyridine-2-carboxamide;

(1R,5S)-N-ethyl-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octane-8-carboxamide;

[(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone;

(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5R,6R)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-6-methyl-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-cyano-N-[(1S,5S)-3-{5-fluoro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-5-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-1-yl]cyclopropanecarboxamide;

(1R,2R)-2-[[[(1R,5S)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl]cyclopropanecarbonitrile;

5-({4-[(1R,5S)-8-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-methylpyridine-2-carboxamide;

5-({4-[(1R,5S)-8-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]pyrimidin-2-yl}amino)-3-fluoropyridine-2-carboxamide

and,

4-({(1R,5S)-8-[(2,2-difluorocyclopropyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl}-N-(1H-pyrazol-4-yl)pyrimidin-2-amine;

or, a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of multiple sclerosis.